ABSTRACT
INTRODUCTION
length E9L gene was amplified as five (CMLV) or four (VACV and CPXV) overlapping amplicons using animal experimentations were completed in biosafety level 2 facilities. Groups were defined as uninfected 168 (mock-infected) or as VACV-WR-infected. After anesthesia, mice were inoculated intranasally (i.n) with 10 169 µl of phosphate buffer saline (PBS) (uninfected) or with 10 µl of PBS containing 4,000 PFU of VACV-WR
170
(5 µl per nostril). Treatment was given intraperitoneally once daily for 5 consecutive days, beginning 6 h 171 after infection, at a concentration of 5 or 50 mg/kg of KAY-2-41 dissolved in PBS. Cohorts were then 172 monitored for body weight, morbidity and mortality. Reported mortality rates included by both actual 173 mortality (approximately 40% of the infected animals) and mortality due to euthanasia of animals showed 174 that lost more than 30% of their body weight. To determine the extent of viral replication, five mice of the 175 VACV-WR-infected groups having received no treatment or KAY-2-41 at 50 mg/kg were euthanized at day collected and processed as previously described (41 ANPs. In previous studies, we identified such amino acid substitutions in the exonuclease domain of E9L
224
(A314V), in the polymerase domain (T831I), or in both domains (A314V+A684V) (35). Recombinant 225 CML1, CML14 and VACV harboring these amino acid substitutions were used, and the two ANPs cidofovir 226 and (S)-HPMPDAP were included as control drugs to confirm the resistance phenotype of each strain
227
( Table 3) . The presence of the A314V or the T831I mutation did not alter the sensitivity of VACV, CML1
228 and CML14 to KAY-2-41, while these amino acid substitutions conferred resistance to cidofovir and/or (S)-appeared to render CML14 and VACV even more sensitive to the effect of KAY-2-41, albeit the shifts in
231
EC 50 values, when compared to the WT viruses, were only 4.6-fold (0.10 µM versus 0.46 µM, p = 0.0164, 232 CML14) and 3.85-fold (0.2 µM versus 0.77 µM, p = 0.0173, VACV) ( Table 3) . On the other hand, the 233 A314V+A684V substitutions were responsible for high levels of resistance to cidofovir and (S)-HPMPDAP.
234
In conclusion, KAY-2-41 was endowed with potent antiviral efficacy against cidofovir-resistant viruses, and 235 the molecule appeared to have a slightly increased activity when the A314V+A684V mutation was present. 
252
We further proceeded to the phenotypic characterization of the KAY-2-41 R clones. As shown in Figure 3 A-253 C, relatively low levels of drug-resistance to KAY-2-41 were found for the mutant viruses as they were only Cross-resistance to 5-BrdU reinforced this conclusion as it partially relies on viral TK to be active.
265
Additionally, the TK negative phenotype of each of the KAY-2-41 R OPVs was confirmed by the ability of 266 these viruses to multiply in H143B TK-deficient cells in the presence of KAY-2-41 or 5-BrdU concentration 267 which was inhibitory for the WT viruses (data not shown).
268
We also evaluated the potential involvement of the ribonucleotide reductase in KAY-2-41 efficacy by using DNA copies/g), liver (mean of 1.2 versus 6.6 log DNA copies/g), spleen (mean of 4.5 versus 6.3 log DNA 306 copies/g) and serum (mean of 2.5 versus 4.2 log DNA copies/g). A similar trend was also noticed in the KAY-2-41-treated animals which strikingly contrasts with the interstitial inflammation seen in infected 310 untreated animals ( Figure 5C ). 
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